Dissertations / Theses on the topic 'Treatment of inflammatory disease'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 dissertations / theses for your research on the topic 'Treatment of inflammatory disease.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse dissertations / theses on a wide variety of disciplines and organise your bibliography correctly.
Maiden, Laurence Peter. "Gastrointestinal inflammation : non steroidal anti-inflammatory drugs and inflammatory bowel disease; novel evaluation and treatment of disease." Thesis, King's College London (University of London), 2008. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.497608.
Full textRobinson, Richard John. "Osteoporosis in inflammatory bowel disease : aetiology, diagnosis and treatment." Thesis, University of Leicester, 1998. http://hdl.handle.net/2381/29557.
Full textLindberg, Johan. "Transcriptional patterns in inflammatory disease." Doctoral thesis, Stockholm : Bioteknologi, Kungliga Tekniska högskolan, 2008. http://urn.kb.se/resolve?urn=urn:nbn:se:kth:diva-9117.
Full textWolf, Stefan. "Novel Approaches in the Treatment of Virus- Induced Inflammatory Disease." Thesis, Griffith University, 2016. http://hdl.handle.net/10072/366853.
Full textThesis (PhD Doctorate)
Doctor of Philosophy (PhD)
Institute for Glycomics
Science, Environment, Engineering and Technology
Full Text
Bailey, Mark Allan. "Synthesis and Analysis of Novel Anti-Inflammatory Conjugates for the Treatment of Inflammatory Bowel Disease." Thesis, University of Brighton, 2007. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.485757.
Full textMitchison, Harriet Caroline. "Primary biliary cirrhosis : studies in prognosis, early diagnosis, bone disease and treatment." Thesis, University of Newcastle Upon Tyne, 1990. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.241281.
Full textSmith, Melissa Ann. "Optimising the use of Azathioprine in the treatment of Inflammatory Bowel Disease." Thesis, King's College London (University of London), 2016. https://kclpure.kcl.ac.uk/portal/en/theses/optimising-the-use-of-azathioprine-in-the-treatment-of-inflammatory-bowel-disease(c05015ac-a88a-4322-b457-200af7c11118).html.
Full textSALA, EMANUELA. "MESENCHYMAL STEM CELLS: MECHANISMS INVOLVED IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE." Doctoral thesis, Università degli Studi di Milano, 2013. http://hdl.handle.net/2434/218985.
Full textLiefferinckx, Claire. "Evaluation of disease severity in inflammatory bowel diseases: From predictive diagnostic gene markers to treatment optimization based on pharmacokinetics." Doctoral thesis, Universite Libre de Bruxelles, 2019. https://dipot.ulb.ac.be/dspace/bitstream/2013/286479/3/table.docx.
Full textDoctorat en Sciences biomédicales et pharmaceutiques (Médecine)
info:eu-repo/semantics/nonPublished
Schmitz, Silke. "Investigations into the efficacy of probiotics in canine inflammatory bowel disease." Thesis, Royal Veterinary College (University of London), 2014. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.618324.
Full textNguyen, Truc. "In Vivo Genotoxicity and Selection Associated with Thiopurine Treatment in Subjects with Inflammatory Bowel Disease." ScholarWorks @ UVM, 2008. http://scholarworks.uvm.edu/graddis/160.
Full textBrent, Meredith. "Therapeutic Processes in a Cognitive-Behavioral Treatment for Depressed Adolescents with Inflammatory Bowel Disease." DigitalCommons@USU, 2006. https://digitalcommons.usu.edu/etd/6220.
Full textNosadini, Margherita. "Clinical and therapeutic decision making in paediatric autoimmune and inflammatory neurological disease." Doctoral thesis, Università degli studi di Padova, 2017. http://hdl.handle.net/11577/3427168.
Full textMcBride, Eileen. "The development of a novel drug delivery system for the treatment of inflammatory bowel disease." Thesis, University of Strathclyde, 2008. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.501659.
Full textBlattner, Kevin Michael. "Design, synthesis and evaluation of 5-HT7 antagonists for the treatment of Inflammatory Bowel Disease." Diss., Temple University Libraries, 2018. http://cdm16002.contentdm.oclc.org/cdm/ref/collection/p245801coll10/id/529694.
Full textPh.D.
The 5-HT7¬ receptor is the most recently discovered 5-HT receptor subtype. 5-HT7 is a GPCR that exhibits a regulatory role in many biological functions in both the central nervous system (CNS) and the periphery. Recent literature has demonstrated a connection between the 5-HT7 receptor and Inflammatory Bowel Disease (IBD) progression. IBD is a devastating disease that affects 1.4 million Americans. Patients suffer from life altering symptoms as a result of severe, chronic inflammation of the gastrointestinal tract. Current treatments mitigate symptoms with no effect on disease progression. Targeting the 5-HT7 receptor as a novel treatment option is a viable medicinal chemistry project that could result in a therapy capable of providing relief to IBD patients. A novel series of butyrolactones were discovered during a prior thesis project completed by Dr. Rong Gao at Temple University’s School of Pharmacy. Broad screening indicated that many of the compounds within this series were potent binders of the 5-HT7 receptor. These results led to the initiation of a medicinal chemistry program aimed at the development of this series with the intent to identify novel 5-HT7 receptor antagonists that are suitable for pre-clinical and clinical evaluation for the treatment of IBD. Medicinal chemistry strategies were utilized in order to optimize each structural aspect of the butyrolactone pharmacophore. This required the preparation of several small series of compounds wherein one structural feature was systematically changed while the remaining features were held constant. The particular properties that were studied for optimization included 5-HT7 affinity, subtype selectivity, liver microsomes stability (mouse and human), and the topological polar surface area (to minimize CNS penetration). Implementing these strategies led to the identification of potent 5-HT7¬ antagonists, some of which exhibited excellent subtype selectivity and improved mouse liver microsome stability. Two analogs, 170073 and 230168, were chosen for further study. Both analogs exhibited adequate in vivo pharmacokinetic profiles capable of supporting efficacy in an in vivo setting. 170073 distributed rapidly and extensively into brain tissue, while 230168 moderately distributed into brain tissue. Moving forward, reducing CNS penetration will become a top priority. These two compounds were examined in the DSS induced mouse model of IBD and both exhibited efficacy. Specifically in the acute DSS model of colitis, 170073 and 230168 significantly lowered the disease activity index, mitigated histological damage and reduced the production of proinflammatory cytokines. In addition, 170073 demonstrated efficacy in the chronic DSS model of colitis. 230168 has yet to be tested in the chronic model. The results of this dissertation support the validity of this project and the use of 5-HT7¬ ¬¬antagonists as a potential novel treatment option for IBD.
Temple University--Theses
Cover, Natasha Faith. "A Novel Device and Nanoparticle-Based Approach for Improving Diagnosis and Treatment of pelvic Inflammatory Disease." Scholar Commons, 2012. http://scholarcommons.usf.edu/etd/4020.
Full textBillerey-Larmonier, Claire. "Novel therapeutic strategy for the treatment of Inflammatory Bowel Diseases." Diss., The University of Arizona, 2010. http://hdl.handle.net/10150/194617.
Full textDavies, Gareth Robert. "Intestinal injury due to non-steroid anti-inflammatory drugs : studies of its measurement, pathogenesis, treatment, and relationship to disease activity of inflammatory arthropathies." Thesis, Imperial College London, 1997. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.285154.
Full textLundberg, Sofie. "Nitric oxide and evaluation of different treatments in experimental colitis and inflammatory bowel disease /." Stockholm, 2006. http://diss.kib.ki.se/2006/91-7140-930-0/.
Full textSeixas, João Daniel da Silva. "Development of CO-releasing molecular for the treatment of inflammatory diseases." Doctoral thesis, Universidade Nova de Lisboa. Instituto de Tecnologia Química e Biológica, 2011. http://hdl.handle.net/10362/5797.
Full textCarbon Monoxide, CO, has been recognized as an endogenously produced, potent biological mediator involved in many defense mechanisms both in physiologic and pathologic situations. As a result of these signaling processes, CO possesses a strong therapeutic potential on a wide range of disease indications. However, the hardly avoidable safety and practical problems associated with therapeutic inhalation of toxic CO gas, led to the search for molecules capable of delivering CO to tissues in a living organism in a controlled and therapeutically useful manner. From all the areas of the chemical space where such CO-Releasing Molecules (CO-RMs) can be found, Metal Carbonyls Complexes (MCCs) seems to be the most versatile. It is the purpose of this Thesis to provide an extensive characterization of the behavior of MCCs in the presence of biological molecules and media, in order to identify the chemical and structural parameters that are more relevant to define the profile of a therapeutically effective metal-based CO-RM drug.(...)
This Thesis was financially supported by Fundacao para a Ciencia e Tecnologia, European Social Fund grant number SFRH/BDE/15501/2004 and ALFAMAResearch and Development of Pharmaceutical Drugs Ltd
Gaffney, Jessica. "The Benefits of Nutritional Treatments for Very Early Onset Inflammatory Bowel Disease (VEO-IBD) Patients." Scholarship @ Claremont, 2018. http://scholarship.claremont.edu/cmc_theses/1808.
Full textLuo, Dan, and 骆丹. "Anti-inflammatory mechanisms of compound C from gastrodia and uncaria decoction, a commonly used post-stroke decoction." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2012. http://hdl.handle.net/10722/211556.
Full textpublished_or_final_version
Paediatrics and Adolescent Medicine
Master
Master of Philosophy
Blaker, Paul Andrew. "A search for novel biomarkers predicting toxicity and response to thiopurine treatment in patients with inflammatory bowel disease." Thesis, King's College London (University of London), 2014. http://kclpure.kcl.ac.uk/portal/en/theses/a-search-for-novel-biomarkers-predicting-toxicity-and-response-to-thiopurine-treatment-in-patients-with-inflammatory-bowel-disease(7113dbba-470c-4bbd-a5d6-2cb861b3dfdf).html.
Full textHedén, Blomqvist Ebba. "Evaluation of medical and/or surgical treatment of anosmia/hyposmia in association with inflammatory disease of the upper airway /." Stockholm, 2004. http://diss.kib.ki.se/2004/91-7349-930-7.
Full textMcLoughlin, Claire Marie. "Effect of 7-nitroindazole and related indazoles on inducible nitric oxide synthase : implications for the treatment of septic shock." Thesis, King's College London (University of London), 2002. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.271333.
Full textBeneke, Jeanine. "Obesity as a metabolic syndrome determinant and the influence of physical activity in treatment and prevention / Jeanine Beneke." Thesis, North-West University, 2005. http://hdl.handle.net/10394/1020.
Full textThe prevalence of obesity in both the developed and developing world have increased, which leads to diverse health outcomes and is placing a heavy burden on the economy. Abdominal obesity proved to be one of the main features in predicting metabolic and cardiovascular disease (CVD) risk and may be the link that unifies the metabolic syndrome (MS) through pro-inflammatory pathways. While the pathogenesis of the MS and each of its components are complex and not well understood, abdominal obesity remains the mechanism that relates to increased lipolysis causing the liver to increase blood glucose and very low lipoprotein output. This in turns leads to raised blood glucose, triglycerides, low-density lipoprotein cholesterol (LDL-C), blood pressure and inflammatory markers (C-reactive protein, interleukin-6 and tumor necrosis factor-a) and decreased high-density lipoprotein cholesterol (HDL-C). Prevention of the metabolic syndrome and treatment of its main characteristics are now considered of utmost importance in order to combat the increased CVD risk and all-cause mortality. Decreasing sedentary behaviour through regular physical activity is a key element in successful treatment of obesity through an increase in energy expenditure, but the ability to decrease low-grade systemic inflammation may be an even greater outcome. Aims The aims of this study was firstly, to determine by means of a literature review, how obesity could be related to a state of chronic systemic inflammation (increased CRP and IL-6). Secondly to determine whether physical activity could serve as a suitable method to decrease inflammation associated with obesity and related disorders. Thirdly to determine if abdominal obesity is a predictor of the metabolic syndrome and CVD and finally, to determine if measures of obesity can predict risk for the metabolic syndrome and CVD risk. Methods For this review study, a computer-assisted literature search were utilized to identify research published between 1990 and 2005. the following databases were utilized for the search: NEXUS, Science Direct, PubMed and Medline. Keywords related to obesity (abdominal obesity, overweight), metabolic syndrome (insulin resistance syndrome, dysmetabolic syndrome, syndrome X), cardiovascular disease (coronary heart disease, coronary artery disease), cardiovascular risk factors (hypertension, dyslipidemia, diabetes mellitus, physical activity), inflammatory markers (CRP, IL-6, chronic low-grade inflammation) and physical activity (fitness, exercise and training) were included as part of the search, including the references identified by previous reviewers (not identified as part of the computerized literature search). Results and conclusions Several research studies concluded that obesity could be an inflammatory disorder due to low-grade systemic inflammation. Adipose tissue is known to be a sectretory organ producing cytokines, acute phase reactants and other circulating factors. The synthesis of adipose tissue TNF-a could induce the production of IL-6, CRP and other acute phase reactants. CRP is a acute phase reactant, synthesized primarily in hepatocytes and secreted by the liver in response to a variety of inflammatory cytokines of which IL-6 and TNF-a are mainly involved. CRP increases rapidly in response to trauma, inflammation and infection. Thus, enhanced levels of CRP can be used as a marker of inflammation. Several studies of large population cohorts provide evidence for an inverse, independent dose-response relation between plasma CRP concentration and level of physical activity in both men and women. Trends for decreased IL-6, TNF-a and CRP concentrations were linear with increasing amounts of reported exercise in most of the research studies, physical activity proved effective in lowering measures of adiposity (BMI, WHR, WC and percentage body fat) and obesity related inflammatory markers (CRP & IL-6). Thereby indicating a potential anti-inflammatory effect. In the studies reviewed in this article abdominal obesity is identified as a predictor and independent risk factor for CVD in both men and women. High levels of deep abdominal fat have also been correlated with components of the metabolic syndrome, glucose intolerance, hyperinsulinemia, hypertension, diabetes, increases in plasma triglyceride levels and a decrease in HDL-C levels (dyslipidemia) in many of the studies. Prospective epidemiological studies have revealed that abdominal obesity (determined by WC and WHR) conveys an independent prediction of CVD risk and is more relevant compared to general obesity (determined by BMI). Abdominal fat has been linked to metabolic risk factors like high systolic blood pressure, atherogenic dyslipidemia, with increased serum TG and decreased HDL-C, and glucose intolerance. Although magnetic resonance imaging (MRI) and computerized tomography (CT) have been used successfully in many studies to measure adipose compartments of the abdomen (subcutaneous and visceral fat), anthropometrical measures like WHR and WC have been proven to be an effective measure in predicting the metabolic syndrome. WC has also been included in the metabolic syndrome definitions of the WHO, ATP Ill and new IDF.
Thesis (M.A. (Human Movement Science))--North-West University, Potchefstroom Campus, 2006.
Mahmood, Dler Faieeq Darweesh. "Thioredoxin-1 (Trx1) : a new target in the treatment of cardiovascular diseases." Phd thesis, Université Pierre et Marie Curie - Paris VI, 2014. http://tel.archives-ouvertes.fr/tel-01069096.
Full textBasso, Paulo José. "Avaliação dos efeitos imunomoduladores de estatinas e glicocorticoides na terapêutica da colite experimental." Universidade de São Paulo, 2015. http://www.teses.usp.br/teses/disponiveis/17/17147/tde-01102015-122551/.
Full textCrohn\'s disease (CD) and Ulcerative colitis (UC) are the main conditions that comprise the Inflammatory Bowel Diseases (IBD). The conventional drug therapies for IBD aim to attenuate the uncontrolled inflammation in the intestinal mucosa, to treat the complications and to extend clinical remission. However, all available drugs have unpredictable or limited effects. Glucocorticoids (GCs) are commonly anti-inflammatory drugs, which are associated to refractoriness and/or dependence in over half of IBD patients. On the other hand, statins have pleiotropic properties and the concomitant use with GCs has shown good prospects in several autoimmune and inflammatory diseases, including IBD. Despite the putative clinical improvement after combined use of GCs and statins in IBD, there is a lack of data indicating their additive effects on the immune system. Therefore, the purpose of this study was to evaluate the immune modulatory effects of the concomitant use of statins and GCs in experimental colitis induced by dextran sulfate sodium (DSS). The results showed that long-term use of GCs (dexamethasone - DX), alone or associated to statins (atorvastatin - ATO), did not improve the clinical signs and increased the death rates of C57BL/6 mice exposed to DSS, while the opposite was observed after treatment with statins alone. Short-term use of ATO (3 doses), alone or associated to DX, improved the clinical signs and histological parameters in DSS-exposed mice, decreased the number of white blood cells (mainly monocytes), the number of mononuclear cells in the lamina propria (LP), the frequency of CD11b+ cells in the LP, the frequency of CD11b+CD11c+ and CD11b-CD11c+ dendritic cells (DCs) in the spleen and the frequency of IFN--producing CD4+ T cells in the mesenteric lymph nodes (MLN). However, ATO alone or associated to DX lead to increased CD8+ T lymphocytes in the spleen and MLN. Moreover, both therapies containing ATO inhibited the proliferation of in vitro-treated splenocytes, besides decreasing IL-6 and increasing IL-10 synthesis. Differentially, the association of drugs led to a more pronounced effects over the changes mentioned above than the single use of statin and additionally decreased IL-1, IL-17 and IFN- mRNA expression levels at the intestinal tissue, the number of circulating lymphocytes, the number of leukocytes in spleen and MLN and the frequency of CD4+ T lymphocytes in the MLN. In addition, statins and GCs increased the frequency of CD11b-CD11c+ DCs in LP and the Fas-L concentrations in the large intestine. Considering the short-term use of ATO there was increased frequency of CD11b-CD11c+ DCs in MLN, increased frequency of natural killer (NK) cells in the spleen and decreased mRNA expression of PPAR- in the large intestine. The short-term use of DX improved the histology parameters, decreased the number of macrophages and IFN- levels in the colon, reduced the number of circulating leukocytes (mainly lymphocytes), and increased the frequency of CD11b+ cells in spleen and IL-10 synthesis by ex vivo splenocytes. Finally, since both regulatory T cells (Treg) frequency and the splenocytes susceptibility to regulatory signals have not been modified after the different treatments, our findings suggest that single use of statins preserved an efficient and controlled inflammatory response, while the combined use of GCs and statins led to immunosuppression, which probably contributed to long-term clinical complications of DSS-induced colitis.
Ali, Hussain [Verfasser], and Claus-Michael [Akademischer Betreuer] Lehr. "Budesonide loaded pH-sensitive PLGA nanoparticles for the treatment of inflammatory bowel disease / Hussain Ali. Betreuer: Claus-Michael Lehr." Saarbrücken : Saarländische Universitäts- und Landesbibliothek, 2013. http://d-nb.info/1053724632/34.
Full textSingh, Sachinkumar B. P. "Assessing the long-term clinical effectiveness of inhaled and anti-inflammatory therapies for lung disease in cystic fibrosis." Diss., University of Iowa, 2014. https://ir.uiowa.edu/etd/6502.
Full textOxelmark, Lena. "Quality of life in inflammatory bowel diseases: aspects on interventions and unconventional treatments /." Stockholm, 2006. http://diss.kib.ki.se/2006/91-7140-655-7/.
Full textVlahou, Christina-Helen. "Predictors of treatment adherence in adolescents with inflammatory bowel disease the role of age, body satisfaction and prospective memory in medication and diet behavior. /." unrestricted, 2007. http://etd.gsu.edu/theses/available/etd-04062007-101316/.
Full textTitle from title page. Lindsey L. Cohen, committee chair; Lisa Armistead, Erin B. McClure, Mary K. Morris, committee members. Electronic text (113 p. : ill. (some col.)) : digital, PDF file. Description based on contents viewed Oct. 11, 2007. Includes bibliographical references (p. 73-80).
Vlahou, Christina Helen. "Predictors of Treatment Adherence in Adolescents with Inflammatory Bowel Disease: The Role of Age, Body Satisfaction and Prospective Memory in Medication and Diet Behavior." Digital Archive @ GSU, 2007. http://digitalarchive.gsu.edu/psych_diss/26.
Full textGrimm, Scott Wayne 1961. "THE EFFECT OF PIRFENIDONE ON CHRYSOTILE ASBESTOS-INDUCED PULMONARY FIBROSIS IN THE HAMSTER (ANTI-INFLAMMATORY DRUG)." Thesis, The University of Arizona, 1986. http://hdl.handle.net/10150/276781.
Full textMamba, Phiwokuhle Bongisile. "Bioactivity of selected medicinal plants used for the treatment of sexually transmitted diseases." Diss., University of Pretoria, 2017. http://hdl.handle.net/2263/60834.
Full textDissertation (MSc)--University of Pretoria, 2017.
Plant Science
MSc
Unrestricted
Mills, Sarah Catherine. "The immunoregulatory effects of polyunsaturated fatty acids on dendritic cells and their significance in the aetiology and treatment of inflammatory bowel disease." Thesis, Imperial College London, 2006. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.430543.
Full textCOLETTA, MARINA. "IMMUNOLOGIC PREDICTORS OF RESPONSE TO VEDOLIZUMAB TREATMENT IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: RESULTS OF A PHASE IV PROSPECTIVE INTERVENTIONAL TRIAL." Doctoral thesis, Università degli Studi di Milano, 2019. http://hdl.handle.net/2434/666203.
Full textRobertson, James. "Polymersome mediated intracellular delivery : a tool for research and treatment of infectious and inflammatory diseases." Thesis, University of Sheffield, 2014. http://etheses.whiterose.ac.uk/7619/.
Full textGiulbudagian, Michael [Verfasser]. "Development and Adaptation of Thermoresponsive Nanogels for the Treatment of Inflammatory Skin Diseases / Michael Giulbudagian." Berlin : Freie Universität Berlin, 2018. http://d-nb.info/1150238054/34.
Full text陳智恆 and Chi-hang Chan. "A study of the physiological roles of proteoglycans in the inflammatory bronchial environment of patients with bronchiectasis." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2003. http://hub.hku.hk/bib/B30408751.
Full textKhurrum, Shaista Fatima. "Antisense IL-4 constructs as possible therapeutic tools for treatment of asthma and other inflammatory diseases." Thesis, Queen Mary, University of London, 2005. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.415222.
Full textAleong, Rosanne. "The effect of non-steroidal anti-inflammatory drugs on in vitro glial apolipoprotein E expression - implications for the mechanisms and treatment of Alzheimer's disease /." Thesis, McGill University, 2002. http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=32747.
Full textSaid, Zulfahmi. "Analysis of corticosteroid drug delivery using tissue engineered oral mucosa for the treatment of inflammatory mucosal diseases." Thesis, University of Sheffield, 2018. http://etheses.whiterose.ac.uk/22529/.
Full textKorsun, Stanislav [Verfasser], and Alois [Akademischer Betreuer] Fürst. "Gracilis muscle transposition for treatment of recurrent anovaginal, rectovaginal, rectourethral, and pouch–vaginal fistulas in patients with inflammatory bowel disease / Stanislav Korsun ; Betreuer: Alois Fürst." Regensburg : Universitätsbibliothek Regensburg, 2019. http://d-nb.info/118990554X/34.
Full textProta, Lucia. "Design and characterization of DPI (dry powder inhaler) for the pulmonary delivery of anti-inflammatory and antibiotic drugs in the treatment of cystic fibrosis disease." Doctoral thesis, Universita degli studi di Salerno, 2012. http://hdl.handle.net/10556/600.
Full textThe aim of the present PhD project was to design inhalable powder-based formulations for pharmaceutical products that may improve the treatment of pulmonary diseases, mainly cystic fibrosis, and may be easier for patients to use. Particularly, the present project aims to supply CF patients with flavonoids (Naringin) and aminoglycosides (Gentamicin sulfate) in a respirable form as a valid alternative over more conventional (oral or parenteral) anti-inflammatory and antibiotic therapy. As a matter of fact, in CF epithelial cells, antioxidant defense systems appear to be defective in their ability to control the amount of ROS produced and over abundance of ROS may cause tissue injury-events and modify intracellular signalling pathways leading to enhanced inflammatory processes, typical of CF airways. Overall, evidence suggests improved CFTR function in vitro when flavonoids, such as genistein, are used. For chronic Pseudomonas aeruginosa (Pa) infections in CF, gentamicin given by pulmonary route may plays important role. In fact, it was observed daily inhalation of some aminoglycosides from nebulized solution delays the acquisition of chronic Pa infections and decreases CF progression. The project address a number of the key features that are outstanding in inhaled delivery, mainly - characteristic of the active drug; - properties of the drug formulation, particularly powder flow, particle size, shape, surface properties and drug/carrier interaction; - consistent dose delivery and high proportion of dose getting to the lung; - performance of the inhaler device, including aerosol generation and delivery. A balance among these characteristics is necessary in the design of a drug formulation intended for pulmonary administration. Utilizing proven (Spray-drying) or innovative (Supercritical Assisted Atomization) technology, stable and micronized powders usefull for dry powder inhaler (DPI) production have been developed. Moreover, the research has been based on in vitro product test methods to evaluate the health effects of produced powders and their aerodynamic behaviour through the pulmonary system. Optimized stability and bioavailability of the selected drugs, the achieving of therapeutically effective concentrations for the pulmonary care of cystic fibrosis have been other goals of the research. Technologies and products that the research is aimed to develop would be of interest to a number of pharmaceutical companies either in the respiratory area or trying to get a toehold in this market. Specific objectives of this research have been: design and development of Dry Powder Inhalers (DPIs) containing flavonoids (Naringin) or aminoglycoside antibiotics (Gentamicin sulfate) micronized powder by spray drying production or by Supercritical Assisted Atomization (SAA); optimization of the aerodynamic characteristics of the powders, through the use of excipients (amino acids) not toxic for lung but able to improve the powder flow properties and dispersion which, in turn, may increase lung deposition of the drugs; in vitro evaluation of the biological activity of the engineered particles on a model of bronchial epithelial cell lines from patients with cystic fibrosis (CuFi1, F508del/F508del CFTR), in comparison to the activity of the same products on normal bronchial epithelial cell lines (NuLi1). (edited by author)
X n.s.
Banz, Kelly. "Calming the ocular storm : the effect of corticosteroids in inflammatory oedema." University of Western Australia. Faculty of Life and Physical Sciences, 2009. http://theses.library.uwa.edu.au/adt-WU2009.0093.
Full textTokar, O. M. "Optimization of the scheme of treatment of inflammatory diseases of periodontal tissues in workers of the primary woodworking industry." Thesis, БДМУ, 2021. http://dspace.bsmu.edu.ua:8080/xmlui/handle/123456789/19131.
Full textMurray, Lynda. "The effects of combined creatine monohydrate supplementation and physical training on body composition and muscular function in patients with inflammatory myopathies." Thesis, Edith Cowan University, Research Online, Perth, Western Australia, 2005. https://ro.ecu.edu.au/theses/677.
Full textShabani, Fariba. "Regulation of matrix metalloproteinases, their inhibitors and IL-8 in inflammatory rheumatic diseases : effects of cytokines and anti-rheumatic agents /." Title page and contents only, 1997. http://web4.library.adelaide.edu.au/theses/09PH/09phs524.pdf.
Full textGuillot, Alexis [Verfasser], and Claus-Michael [Akademischer Betreuer] Lehr. "Analyzing drug load and release from pharmaceutical nanocarriers for the treatment of inflammatory bowel diseases / Alexis Guillot. Betreuer: Claus-Michael Lehr." Saarbrücken : Saarländische Universitäts- und Landesbibliothek, 2015. http://d-nb.info/1071087371/34.
Full text